The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly-ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors.
 
Craig L. Slingluff
Consulting or Advisory Role - Immatics (Inst); Polynoma (Inst)
Research Funding - 3M (Inst); GlaxoSmithKline (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - UVA Licensing and Ventures Group
 
Daniel Dasilva
No Relationships to Disclose
 
Paul Schwarzenberger
No Relationships to Disclose
 
Toni Ricciardi
Employment - Cascade Medical Enterprises
Stock and Other Ownership Interests - Becton Dickinson; Cascade Medical Enterprises
Consulting or Advisory Role - Cascade Medical Enterprises
 
Mary J. Macri
Employment - Eisai
Stock and Other Ownership Interests - Pfizer
 
Aileen Ryan
Stock and Other Ownership Interests - Amgen; Immunogen; Teva
 
Ralph Rudolph Venhaus
Stock and Other Ownership Interests - Dynavax Technologies; Soligenix
 
Nina Bhardwaj
Employment - Irving Surgery and Wellness Center (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb; Merck; Pfizer
Consulting or Advisory Role - CureVac
Patents, Royalties, Other Intellectual Property - Argos Therapeutics
Other Relationship - Parker Institute for Cancer Immunotherapy